These include drugs that block IgE, cysteinyl leukotrienes and the use of immunotherapy as all three approaches have evidence to support their usage in patients with asthma and AR.[15–19] The ideal study design would compare the benefits of a sole lower airway approach with a combined approach in patients with asthma alone and asthma with rhinitis. This evidence concerns the gene IGHE and asthma.